The REACH Studies in Steroid-Refractory Acute GVHD
Part 1: Overall Response Rate, Including by Grade and Organ
Oncologist Dr Michael Bishop reviews the primary efficacy data and safety profile from the REACH1* and REACH2 clinical studies evaluating Jakafi in patients with steroid-refractory aGVHD.
*aGVHD, acute graft-versus-host disease; REACH, Ruxolitinib in PatiEnts with RefrACtory Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation.
Data from REACH2 are not included in the FDA-approved Prescribing Information for Jakafi. FDA approval for Jakafi for the treatment of steroid-refractory acute GVHD was based on data from the REACH1 study.